Cell-Penetrable Parkin Proteins Suppress Parkinson Disease-Associated Phenotypes in Cultured Cells and Animals

Tam Duong1, Jaetaek Kim2, H. Earl Ruley3, Daewoong Jo1,4,¤

1 Department of Biomedical Sciences, Chonnam National University Medical School, Kwangju, Korea, 2 Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Korea, 3 Department of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America, 4 ProCell R&D Institute, ProCell Therapeutics, Inc., Seoul, Korea

Abstract

Parkinson’s disease (PD) is a neurodegenerative disorder of complex etiology characterized by the selective loss of dopaminergic neurons, particularly in the substantia nigra. Parkin, a tightly regulated E3 ubiquitin ligase, promotes the survival of dopaminergic neurons in both PD and Parkinsonian syndromes induced by acute exposures to neurotoxic agents. The present study assessed the potential of cell-permeable parkin (CP-Parkin) as a neuroprotective agent. Cellular uptake and tissue penetration of recombinant, enzymatically active parkin was markedly enhanced by the addition of a hydrophobic macromolecule transduction domain (MTD). The resulting CP-Parkin proteins (HPM13 and PM10) suppressed dopaminergic neuronal toxicity in cells and mice exposed to 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). These included enhanced survival and dopamine expression in cultured CATH.a and SH-SY5Y neuronal cells; and protection against MPTP-induced damage in mice, notably preservation of tyrosine hydroxylase-positive cells with enhanced dopamine expression in the striatum and midbrain, and preservation of gross motor function. These results demonstrate that CP-Parkin proteins can compensate for intrinsic limitations in the parkin response and provide a therapeutic strategy to augment parkin activity in vivo.

Introduction

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. These striking clinical features have focused efforts to understand the mechanisms responsible for neuronal death and reasons why dopaminergic neurons are differentially affected. An extensive literature implicates oxidative stress, mitochondrial dysfunction and protein misfolding in disease etiology [1,2], as illustrated by loss-of-function mutations in genes influencing parkin recruitment to distressed mitochondria and their subsequent removal by mitophagy. DJ-1, although associated with diverse functions, appears to play a parallel protective role to that of parkin/PINK1 in oxidative stress response. Agents capable of inducing stable Parkinson-like symptoms include chemical neurotoxins, notably 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone and 6-hydroxy-dopamine (6-OHDA) and α-synuclein, a protein that accumulates in Lewy bodies, a clinical signature of human PD [4]. These agents promote neuronal degeneration/dysfunction through a combination of oxidative stress and mitochondrial respiratory impairment.

Despite the complexity of PD etiology, parkin appears to play a broadly protective role in maintaining neuronal function and viability. These protective effects extend to a variety of neurotoxins, mitochondrial poisons and misfolded proteins including: dopamine [5], rotenone and carbonyl cyanide 3-chlorophenylhydrazone [6], 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), excitotoxin (kainic acid) [7], unfolded protein stress response [8], β-amyloid precursor protein [6], Pacl receptor

Citation: Duong T, Kim J, Ruley HE, Jo D (2014) Cell-Permeable Parkin Proteins Suppress Parkinson Disease-Associated Phenotypes in Cultured Cells and Animals. PLoS ONE 9(7): e102517. doi:10.1371/journal.pone.0102517

Editor: Michelle L. Block, Virginia Commonwealth University, United States of America

Received January 27, 2014; Accepted June 19, 2014; Published July 14, 2014

Copyright: © 2014 Duong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by a grant of the Rising Professor Support Program (KRF-2006-331-E00102 to D.J.) of Ministry of Education, Science and Technology, Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Daewoong Jo was the founding scientist of ProCell Therapeutics, Inc., and is affiliated with Vanderbilt University at present. Hereby, Daewoong Jo discloses a financial interest in the company. The other authors disclosed no potential conflicts of interest. ProCell Therapeutics, Inc. has filed a patent for “cell-permeable recombinant parkin protein and a pharmaceutical composition for treating degenerative brain diseases containing the same” under the names of Daewoong Jo, Chanki Kim, Jung-Hee Lim, Yoori Choi, and Hee-Hyun Kim. The relevant application number is PCT/KR2011/007682. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* Email: dae-woong.jo@vanderbilt.edu
¤ Current address: Department of Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America

Introduction

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. These striking clinical features have focused efforts to understand the mechanisms responsible for neuronal death and reasons why dopaminergic neurons are differentially affected. An extensive literature implicates oxidative stress, mitochondrial dysfunction and protein misfolding in disease etiology [1,2], as illustrated by loss-of-function mutations in genes influencing parkin recruitment to distressed mitochondria and their subsequent removal by mitophagy. DJ-1, although associated with diverse functions, appears to play a parallel protective role to that of parkin/PINK1 in oxidative stress response. Agents capable of inducing stable Parkinson-like symptoms include chemical neurotoxins, notably 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone and 6-hydroxy-dopamine (6-OHDA) and α-synuclein, a protein that accumulates in Lewy bodies, a clinical signature of human PD [4]. These agents promote neuronal degeneration/dysfunction through a combination of oxidative stress and mitochondrial respiratory impairment.

Despite the complexity of PD etiology, parkin appears to play a broadly protective role in maintaining neuronal function and viability. These protective effects extend to a variety of neurotoxins, mitochondrial poisons and misfolded proteins including: dopamine [5], rotenone and carbonyl cyanide 3-chlorophenylhydrazone [6], 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), excitotoxin (kainic acid) [7], unfolded protein stress response [8], β-amyloid precursor protein [6], Pacl receptor

PLOS ONE | www.plosone.org 1 | July 2014 | Volume 9 | Issue 7 | e102517
[9,10], proteasome inhibitors and α-synuclein [11,12]. Enforced parkin expression also suppresses pathological consequences of PARK1 and DJ-1 gene deficiencies. PARK1 appears to act upstream of parkin, since PARK1 does not complement parkin deficiency. However, both parkin and PARK1 rescue a fragmented mitochondria phenotype of DJ-1 knockout cells, suggesting PARK1/parkin act in parallel with DJ-1 to maintain mitochondrial integrity [1].

These broad cytoprotective activities illustrate the benefits of genetically augmenting parkin levels, and suggest methods to enhance parkin expression and/or activity could provide useful therapies in the treatment of PD. Unfortunately, gene therapy is not a practical option. Moreover, it is not clear if the benefits associated with higher steady-state levels of parkin expression can also be achieved under transient, non-steady state conditions. To address these issues, we developed cell-permeable parkin proteins that we then tested for cytoprotective activity in cultured neuronal cells and in an acute mouse model of PD.

Results

Development of Cell-Permeable Parkin Proteins

Multiple hydrophobic macromolecule transduction domains (MTDs) have been used to enhance the delivery of protein cargoes to mammalian cells and tissues [13–22]. Similarly, MTD01, MTD10, MTD13, MTD151, and MTD174 were found to enhance the uptake of a His-tagged enhanced green fluorescent protein (EGFP) in RAW cells as assessed by flow cytometry (Figure S1A). Relative levels of protein uptake were 0.8 to 3.6 times that of a protein (HM(E) containing the membrane translocation sequence (MTS) from FGF4 (Hawiger, 1999) (Table S1). By contrast, only minimal levels of protein uptake were observed with a protein (HSP) with an arbitrary peptide sequence in place of the MTD. Similar results were obtained in NIH3T3 cells, using fluorescent microscopy to monitor protein uptake (Figure S1B). MTD sequences also enhanced protein delivery to a variety of murine tissues after IP administration (Figure S1C).

MTD01, MTD10, MTD13, MTD151, and MTD174, were subsequently tested for the ability to enhance parkin uptake. Recombinant parkin proteins containing a 6xHis-tag alone (HP) or together with MTD01 and MTD13, were expressed in E. coli (Figures 1A, left panel and 1B). However, as we were not satisfied with protein solubility and/or yield, additional parkin proteins were expressed that contained no MTD or MTDs 10, 13, 151 or 174 without a 6xHis-tag (designated P, PM10, PM13, PM151, and PM174, respectively). In addition, the PARK2 sequence in these vectors was modified to employ E. coli codon preferences (Figures 1A, right panel and 1C). The 6xHis-tagged proteins were purified under denaturing conditions by Ni²⁺-affinity chromatography and allowed to refold; whereas the untagged proteins were extracted from inclusion bodies and purified by Q-sepharose anion exchange chromatography (Figure 1C, right panel). In each case, proteins lacking the 6xHis tag were expressed at higher levels from codon-optimized vectors and produced greater yields of soluble proteins as compared to 6xHis tagged proteins encoded by the human PARK2 sequence (Figures 1B and C; bottom panels). All of the recombinant parkin proteins possessed E3 ubiquitin ligase activity as assessed by an auto-ubiquitination assay (Figure 2 and data not shown).

Purified parkin proteins were labeled with FITC, and protein uptake was tested either in RAW and NIH3T3 cells by flow cytometry (Figure S2A) and fluorescent confocal microscopy (Figure S2B), respectively. Since recombinant parkin proteins were positive charged and sticky, it was hard to remove completely the cell surface-bound proteins, resulting in difficulty to distinguish the internalized quantity from surface-bound proteins. We also monitored systemic delivery of CP-Parkin proteins (after IP administration) in a variety of murine tissues (Figure S1C). By contrast, 6xHis-tagged parkin without an MTD sequence (HP) did not accumulate in any of the cells or tissues examined. Brain sections and lysates also contained up to 6-fold higher levels of HPM01, HPM13 and PM10 as compared to levels of HP or endogenous parkin proteins as assessed by immunohistochemical staining (Figures 3A and B) or Western blot analysis (Figures 3C and D). These experiments established MTD01, MTD10 and MTD13 as vehicles for parkin protein delivery both in cultured cells and in animal tissues.

CP-Parkin Protects Cultured Neuronal Cells from 6-Hydroxydopamine-Induced Apoptosis and Stimulates Dopamine Synthesis

Neuroprotective activities of cell-permeable parkin were tested using an in vitro model of dopamine-induced cytotoxicity. Mouse dopaminergic neuronal cell CATH.a (a catecholaminergic cell line of CNS origin) and SH-SY5Y (derived from a human brain tumor) undergo apoptosis upon treatment with dopamine or dopamine metabolites including 6-hydroxydopamine [23]. As shown in Figure 4A, treatment of CATH.a cells for 1 hr with 50 μM 6-hydroxydopamine (6-OHDA) induced nearly 100% of the cells to undergo apoptosis as assessed by a fluorescent terminal dUTP nick-end labeling (TUNEL) assay. The apoptosis was almost completely blocked by treating cells for 2.5 hrs (starting after 6-OHDA removal) with 2.5 μM HPM13 (Figure 4A, p<0.001). By contrast, HP, a 6xHis tagged parkin protein that lacks an MTD sequence and did not enter cells, was not cytoprotective. Similar results were obtained in SH-SY5Y cells except the cells were exposed to 100 μM 6-OHDA for 6 hrs followed by 2.5 μM PM10, a parkin protein with a different MTD sequence and lacking the 6xHis tag for 2.5 hrs (Figure 4B, p<0.001).

We also examined the ability of parkin proteins to enhance cellular dopamine release, a marker of normal neuronal function in CATH.a cells, pre-treated with 80 μM tyrosine for 24 hrs. Cells treated with cell-permeable parkin protein (HPM13) expressed 2 to 4.8 times higher levels of dopamine 5 hrs after treatment than cells treated with media alone or with 6xHis tagged parkin protein without the MTD sequence (Figure 5A, p<0.001).

Figure S1A
Figure S1B
Figure S1C
Table S1
Figure 1A, left panel and 1B
Figure 1C, right panel and 1C
Figure 1B and C; bottom panels
Figure S2A
Figure S2B
Figure S1A
Figure S1B
Figure S1C
Table S1
Figure 1A, left panel and 1B
Figure 1C, right panel and 1C
Figure 1B and C; bottom panels
Figure S2A
Figure S2B
Figure S1A
Figure S1B
Figure S1C
Table S1
Figure 1A, left panel and 1B
Figure 1C, right panel and 1C
Figure 1B and C; bottom panels
Figure S2A
Figure S2B
Figure S1A
Figure S1B
Figure S1C
Table S1
Figure 1A, left panel and 1B
Figure 1C, right panel and 1C
Figure 1B and C; bottom panels
Figure S2A
Figure S2B
Figure S1A
Figure S1B
Figure S1C
Table S1
Figure 1A, left panel and 1B
Figure 1C, right panel and 1C
Figure 1B and C; bottom panels
Figure S2A
Figure S2B
Figure S1A
Figure S1B
Figure S1C
Table S1
Figure 1A, left panel and 1B
Figure 1C, right panel and 1C
Figure 1B and C; bottom panels
Figure S2A
Figure S2B
Figure S1A
Figure S1B
Figure S1C
Table S1
Figure 1A, left panel and 1B
Figure 1C, right panel and 1C
Figure 1B and C; bottom panels
Figure S2A
Figure S2B
Figure S1A
Figure S1B
Figure S1C
Table S1
Figure 1A, left panel and 1B
Figure 1C, right panel and 1C
Figure 1B and C; bottom panels
Figure S2A
Figure S2B
Figure S1A
Figure S1B
Figure S1C
Table S1
Figure 1A, left panel and 1B
Figure 1C, right panel and 1C
Figure 1B and C; bottom panels
Figure S2A
Figure S2B
Figure S1A
Figure S1B
Figure S1C
Table S1
Figure 1A, left panel and 1B
Figure 1C, right panel and 1C
Figure 1B and C; bottom panels
Figure S2A
Figure S2B
Figure S1A
Figure S1B
Figure S1C
Table S1
Figure 1A, left panel and 1B
Figure 1C, right panel and 1C
Figure 1B and C; bottom panels
Figure S2A
Figure S2B
Figure S1A
Figure S1B
Figure S1C
Table S1
Figure 1A, left panel and 1B
Figure 1C, right panel and 1C
Figure 1B and C; bottom panels
Figure S2A
Figure S2B
Figure S1A
Figure S1B
Figure S1C
Table S1
Figure 1A, left panel and 1B
Figure 1C, right panel and 1C
Figure 1B and C; bottom panels
Figure S2A
Figure S2B

hydroxylase status of primary rat neurons treated in vitro with 6-hydroxydopamine (data not shown).

These experiments do not distinguish the extent to which loss of TH staining (and restoration by CP-Parkin) reflects MPTP-induced neuronal cell loss or suppression of TH expression. Most important with regard to physiological function, gross motor functions were assessed after acute MPTP-induced injury by using a swim test [25,26]. Mice were placed in a water bath and their movements were video recorded for later blind analysis (Figure 6B). While the control mice swam more or less continuously (98% of the time), the lesioned animals were considerably (35%) less active. Mice treated with 6xHis tagged parkin appeared slightly more active (49%) on experimental day 3, but the effect was not statistically significant. By contrast, gross motor functions of HPM13-treated mice were within 25% of the normal controls (p, 0.001) (Figure 6B). The comparisons are MPTP only to MPTP (*); MPTP only to MPTP+HPM13 (**); Diluent to each group [MPTP only, MPTP+HP or MPTP+HPM13] (***)..

Discussion

Since parkin, PINK1 and DJ-1 are widely expressed and oxidative stress, mitochondrial poisons and misfolded proteins presumably affect many cell types, other features of the neuronal phenotype have been proposed to explain the differential vulnerability of dopaminergic (and other) neurons observed in PD [27]. These include dopamine metabolism itself [28,29] and electrophysiologic features of neurons in the substantia nigra, characterized by slow, broad-spike, autonomous pacemaking with low Ca2+ buffering [30]. Both processes induce oxidative stress, placing steady-state burdens on cellular anti-oxidant defenses and...
mitochondrial homeostasis, which in turn are thought to enhance the vulnerability of dopaminergic neurons [27].

The present study demonstrates the effectiveness of protein-based therapy to deliver enzymatically active, cell-permeable (CP) parkin proteins as neuroprotective agents in an acute intoxication model of dopaminergic neuronal loss. CP-Parkin proteins containing MTDs displayed enhanced cellular uptake and tissue penetration as compared to proteins lacking an MTD, and they suppressed Parkinson Disease-associated phenotypes in 6-OHDA- and MPTP-treated cells and animals. In particular, CP-Parkin suppressed 6-OHDA-induced apoptosis in CATH.a and SH-SY5Y cells, stimulated dopamine expression in cultured CATH.a cells, preserved tyrosine hydroxylase positive cells in the striatum and midbrain, enhanced dopamine expression, and preserved gross motor functions (swim test) in MPTP-treated mice.

The levels of cytoprotection achieved by CP-Parkin were comparable to those reported after enforced expression of the parkin gene in neuronal cell lines and in animal models of PD [5,7,11]. This suggests that the activity of systemically delivered HPM13 and PM10 protein approaches theoretical limits associated with augmented parkin function in the different models examined. These results demonstrate that cytoprotective benefits of parkin do not require prolonged prior exposure but can be achieved relatively quickly, under non-steady state conditions.

Cell-permeable proteins used in the present study possessed a low intrinsic auto-ubiquitination activity characteristic of the wild type protein, and the auto-ubiquitination activity was unaltered by the addition of amino-terminal 6xHis or carboxyl-terminal MTD sequences. These results are consistent with previous studies in which parkin appeared to tolerate a variety of amino- and carboxyl-terminal sequences while maintaining normal enzymatic and regulatory functions [31–34]. Although, we were unable to assess potential contributions of the MTD sequence on the biological activity of CP-Parkin due to problems expressing MTD sequences in soluble form, we have observed no effects in cells or tissues treated with other cargos containing MTD sequences, e.g. EGFP (Supplementary Figure S1). Moreover, all of the biological effects attributed to CP-Parkin in cells and mice were similar to those associated with enforced PARK2 gene expression.

Parkin ubiquitination ligase activity is intrinsically repressed due to structural features of the protein that occlude the E2 and catalytic sites [34]. Enzyme activity is regulated by mitochondrial relocalization, post-translational modifications and ligand binding to the ubiquitin-like (Ubl) domain [31–33,35–38]. In addition, the enzyme can be constitutively activated either by deletion of amino-terminal sequences containing the Ubl and zinc-finger RING0 domains or by various missense mutations responsible for juvenile autosomal recessive PD [34]. The latter mutations destabilize the protein as a consequence of enhanced auto-ubiquitination. It will be important to test cell-permeable parkin proteins–engineered either to be constitutively active or to resist auto-ubiquitination–for enhanced cytoprotective activity.

In principle, protein-based therapies offer a way to control biochemical processes in living cells under non steady-state conditions and with fewer off target effects than conventional small molecule therapeutics. However, systemic protein delivery in animals has proven difficult due to poor tissue penetration and rapid clearance [39,40]. Protein transduction exploits the ability of specific basic, amphipathic and hydrophobic protein sequences to enhance the uptake of proteins and other macromolecules by mammalian cells [39,40]. Some success has been achieved using sequences derived from hydrophobic signal peptides to deliver biologically active peptides and proteins to a variety of tissues (including liver, lung, pancreas, lymphoid tissues and brain). The hydrophobic macromolecule transduction domains (MTDs) used in the present study were selected from a screen of more than 1,500 signal peptide sequences. Although the MTDs we developed do not have a common sequence or sequence motif they were all derived from the hydrophobic (H) regions of signal sequences (HRSSs) that also lack common sequences or motifs except their hydrophobicity and the tendency to adopt alpha-helical conformations. The wide variation in H region sequences may reflect...
prior evolution for proteins with membrane translocating activity and subsequent adaptation to the SRP/Sec61 machinery, which utilizes a methionine-rich signal peptide binding pocket in SRP to accommodate a wide-variety of signal peptide sequences. The persistence of H region sequence variability presumably reflects unknown cargo-specific advantages. Similarly we know that specific MTDs work better than others with specific cargos, particularly with regard to maintaining protein solubility, and have published several such examples [13,14,16,18,20–22,41–43].

The development of MTD sequences has been largely empirical, starting with a screen for sequences able to enhance EGFP reporter protein uptake. Individual sequences were further modified to eliminate charged and polar amino acids, increase predicted $\alpha$-helical content and limit the number of consecutive hydrophobic residues. These hydrophobic MTD sequences appear to penetrate the plasma membrane directly [17] after inserting into the membranes [44]. In particular, translocation of the FGF4 MTS [17] occurs after the peptide inserts into the membrane in a “bent” configuration with hydrophobic sequences adopting an $\alpha$-helical conformation [44]. MTD-dependent uptake of proteins was bidirectional as evidenced by cell-to-cell transfer. Cellular uptake was also sensitive to low temperature, did not require microtubule reorganization, was not enhanced by agents that disrupt the plasma membrane, and did not utilize ATP [21]—features consistent with direct membrane penetration. Cell-permeable p18INK4c traversed synthetic membranes consisting of cholesterol and phospholipid and was capable of bidirectional movement across membranes as assessed by cell-to-cell protein transfer [21]. Finally, as reviewed elsewhere [21,43] the presence of an MTD sequence does not preclude uptake by other mechanisms, including adsorptive and fluid-phase endocytosis. As a consequence, the uptake of MTD-containing cargoes is not exclusively cytoplasmic.

Hydrophobic MTD sequences have been used to deliver biologically active peptides and proteins to variety of tissues and tumor xenografts. Striking therapeutic benefits using these MTDs have been reported using a small peptide to protect against otherwise lethal inflammatory responses [13,14,16,42] and using larger cell-permeable proteins including suppressor of cytokine signaling 3 (SOCS3) to protect animals against lethal inflammation [18], the NM23 metastasis suppressor to inhibit the seeding and growth of pulmonary metastases [20], the cyclin-dependent kinase inhibitor, p18INK4c, to inhibit the growth of tumor xenografts [21], the RUNX3 tumor suppressor to suppress the growth of subcutaneous gastric tumor xenografts [22] and the angiogenesis

Figure 4. CP-Parkin protects neuronal cells from 6-OHDA-induced apoptosis. (A) Suppression of apoptosis in dopaminergic CATH.a cells. CATH.a cells at 5% (Low) or 70% (High) confluence were incubated with 50 $\mu$M 6-hydroxydopamine (6-OHDA. Agonist) for 1 hr, treated for 2.5 hrs with 2.5 $\mu$M HP or HPM$_{13}$ and assessed for apoptosis by TUNEL staining. The micrographs (left panels) are representative of three independent experiments, plotted (right panels) as means $\pm$ S.D. Experimental differences between groups were assessed by a Student’s two-paired $t$-test ($^*p<0.001$). (B) Suppression of apoptosis in SH-SYSY cells. Apoptosis in SH-SYSY treated with 6-OHDA with and without PM$_{10}$ was assessed as described in (A). (C) HPM$_{13}$ enhances dopamine release from CATH.a cells. The cells were incubated with 80 $\mu$M tyrosine for 24 hrs, treated for 5 hrs with 2.5 $\mu$M HP or HPM$_{13}$, and levels of secreted dopamine were measured by ELISA. The data are presented as means $\pm$ S.D. of 4 independent experiments. Experimental differences between groups were assessed by a Student’s two-paired $t$-test ($^*p<0.01$ and $^{**}p<0.05$).

doi:10.1371/journal.pone.0102517.g004
inhibitor, Endostatin, to reduce the growth of human tumor xenografts [43].

In the present study we show that the hydrophobic MTD sequence is strictly required for efficient Parkin uptake by cells and for systemic delivery in vivo. Similarly, the widespread tissue distribution and neuroprotective activity of CP-Parkin after intraperitoneal administration illustrates the ability of MTD-containing proteins to penetrate multiple cell and tissue barriers. By contrast, bulk entry mediated by basic protein transduction domains occurs by absorptive endocytosis and macropinocytosis. While the latter approach has suffered from poor tissue penetration and protein bioavailability [39,40], several groups have used the Pep-1 and HIV Tat transduction sequences to deliver a variety of protein cargoes (including SAG, Frataxin, Hsp27, Cdk5, Hsp70, Metallothionein III, and DJ-1) and have reported neuronal protection in acute animal models [45–53] although these studies did not assess the impact of protein therapy on motor functions.

The enhanced cytoprotection and preservation of motor function achieved by CP-Parkin suggests endogenous parkin levels become rate-limiting under conditions of acute intoxication and possibly during the development of progressive PD in the elderly. In short, intrinsic parkin responses appear to be restrained, presumably at the level of basal expression, enzymatic activation and/or post-activation protein turnover initiated by auto-ubiquitination. Such functional restraint and tight biochemical regulation suggest a requirement to guard against gratuitous or compartmentally misplaced ubiquitin ligase activity. Consequently, efforts to modulate parkin activity therapeutically either by constitutively activating the enzyme or by suppressing auto-ubiquitination may be hampered by off-target effects.

Our results demonstrate that exogenously administered parkin proteins can compensate for intrinsic limitations in the parkin response to enhance cytoprotection and preserve motor function following acute intoxication and provide a therapeutic strategy to augment parkin activity and preserve motor function following acute intoxication.

**Materials and Methods**

**Ethics Statement**

This study was carried out in strict accordance with the recommendations in the guidelines of ‘Institutional Review Board (IRB) of the ProCell R&D Institute, ProCell Therapeutics, Inc.’. The protocol was approved by the Committee on the Ethics of Animal Experiments of the ProCell R&D Institute. All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.

**Expression and Purification of Histidine-Tagged EGFP and Parkin Fusion Proteins**

MTD01, MTD13, MTD10, MTD151 and MTD174 were derived from predicted signal sequences of CAC04038,
NP_639877, NP_625021, NP_630126 and NP_733505, respectively. These sequences were selected from a screen of 1,500 proteins as described previously. Histidine-tagged fusion proteins containing EGFP or the full-length 53 kDa parkin protein and MTD01, MTD10, MTD101, MTD103, the FGF4 MTS (Mm, AAVLPVLLAAP) or a random sequence (S, SANVEPLERL) were cloned at NdeI site in pET-28a (+) (Novagen, Darmstadt, Germany) and expressed in E. coli BL21-CodonPlus (DE3) cells. Recombinant EGFP and parkin proteins were named using the following convention: H, E, P and M stand for the His tag; EGFP; parkin and MTD, respectively. Recombinant EGFP proteins were HSE (His-S-EGFP), HM01E (His-MTD01-EGFP), HM03E (His-MTD10-EGFP), HM13E (His-MTD13-EGFP), HM103E (His-MTD103-EGFP), HM101E (His-MTD101-EGFP) and HM151E (His-MTD151-EGFP). Recombinant parkin proteins were HP (His-parkin), HPM01 (His-parkin-MTD01), HPM13 (His-parkin-MTD13), HPM101 (His-parkin-MTD101) and HPM103 (His-parkin-MTD103).

Histidine-tagged recombinant proteins were purified on a Qiagen Ni2+ affinity resin under denaturing conditions and refolded by dialysis against 0.55 M guanidine HCl, 0.44 M L-arginine, 50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 100 mM NDSB, 2 mM reduced glutathione, and 0.2 mM oxidized glutathione for 48 hrs at 4°C and then changed to a physiological buffer such as PBS for in vivo or PBS plus RPMI-1640 medium (1:1) for in vitro assays. Proteins were quantified by the Bradford method, were aliquoted, and stored at -20°C. The purified proteins were judged to have minimum levels of endotoxin as assessed by the limulus amebocyte lysate (LAL) assay (Associates of Cape Cod, Inc., East Falmouth, MA).

Expression and Purification of Histidine-Tag Free Parkin Fusion Proteins

Sequences of E. coli codon-optimized and histidine-tag free recombinant parkin proteins fused to MTDs were also synthesized (Genscript, Piscataway Township, NJ) and cloned at NcoI/HindIII in pUC57 vector, and then finally cloned into pET-
28(±). Histidine-tag free recombinant parkin proteins were P (parkin), PM 15 (parkin-MTD15), PM 13 (parkin-MTD13), PM 11 (parkin-MTD11) and PM 14 (parkin-MTD14).

The proteins were expressed in E. coli BL21-CodonPlus (DE3) cells grown to an A 600 of 0.6 and induced for 3 hrs with 0.5 mM IPTG. Cells were harvested and disrupted by sonication (10 sec/20 sec-off) for 30 min in buffer A (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.1% Triton X-100). Inclusion body was isolated by centrifugation (5,000 rpm for 30 min at 4°C) and dissolved in buffer B (50 mM Tris-HCl, pH 10.0, 8 M urea) for overnight for denaturation. Denatured inclusion body was dialyzed against buffer C (30 mM sodium phosphate, pH 8.0, 0.02% Tween-20) for 48 hrs at 4°C for refolding. Insoluble particles were removed by centrifugation (9,000 rpm for 30 min at 4°C). Purification was conducted by ion-exchange column chromatography with AKTA Purifier FPLC system (GE HealthCare, Pittsburgh, PA). In brief, Q-Sepharose anion column was flowed with protein solution in buffer C for protein binding and washed with buffer D (30 mM sodium phosphate, pH 8.0, 30 mM NaCl) for removing the unbound proteins. Proteins were eluted with salt gradient (30 mM sodium phosphate, pH 8.0, 0.1% Triton X-100) for overnight for dialysis. After purification, proteins were dialyzed against a physiological buffer.

Analysis of Protein Uptake In Vitro and In Vivo

Recombinant proteins were conjugated to 5/6-FITC and uptake by cultured RAW 264.7 (Abelson leukemia virus transformed murine monocyte/macrophage line) and NIH3T3 cells (mouse embryo-derived fibroblasts) were assessed as described previously [21]. Briefly, RAW 264.7 cells were treated with 10 μM FITC-labeled proteins for 1 hr at 37°C, washed with cold PBS three times, and treated with protease K (10 μg/ml) for 20 min at 37°C to remove cell-surface bound proteins. Protein uptake was quantified by flow cytometry (FACSCalibur; BD Biosciences, Billerica, MA).

NIH3T3 cells were exposed to 10 μM FITC-proteins for 30 min and then nuclei were counter stained with 1 μg/ml propidium iodide (Sigma-Aldrich). The cells were washed three times with cold PBS and treated with protease K (10 μg/ml) for 20 min at 37°C to remove cell-surface bound proteins, and examined by confocal laser scanning microscopy.

Balb/c mice (6 weeks old, female) were injected intraperitoneally (i.p., 300 μg/head) with FITC only or FITC-conjugated proteins. After 2 hrs, the liver, kidney, spleen, lung, heart and brain were isolated, washed with an O.C.T. compound (Sakura) and frozen on dry ice. Cryosections (15 μm) were analyzed by fluorescence microscopy.

Immunodetection of MTD Fusion Proteins in Brain Tissue

For immunohistochemistry, 6-week-old Balb/c female mice were injected intraperitoneally with diluent (PBS) or with 200 μg His-tagged recombinant parkin proteins. After 2 hrs, the brains were isolated, fixed with 4% paraformaldehyde for 24 hrs and frozen for cryosectioning. Brain cryosections (15 μm) were immunostained with anti-6xHis tag (1:500, Abcam) or anti-parkin (1:500, Santa Cruz Biotechnology) monoclonal antibodies, followed by biotin-conjugated goat anti-mouse secondary antibody (Santa Cruz Biotechnology), and developed with Avidin-Biotin Complex kit ( Vectastain kit, Vector Laboratories). For western blot analysis, the brains from the mice treated with proteins were isolated, homogenized in RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM EDTA). The supernatant from the centrifugation (13,000 rpm for 10 min at 4°C) was analyzed by western blot that was probed with antibodies against parkin (1:2,000) and β-actin (1:5,000). The secondary antibody was goat anti-mouse IgG-HRP (all antibodies were from Santa Cruz Biotechnology). Separately, mice were injected intravenously (i.v., 200 μg) with diluent or proteins. After 30 hrs, brain tissue lysates were analyzed with anti-parkin antibody.

For parkin proteins without 6xHis tags, 6-week-old Balb/c female mice were injected subcutaneously (SC, 200 μg×3 times, 2 hrs interval) at the left back with diluent or proteins. After 2 hrs of the last injection, the brains were isolated, fixed with 4% paraformaldehyde for 24 hrs and frozen for cryosectioning. Brain cryosections (20 μm) and lysates (100 μg/ml) were immunostained with anti-MTD10 (1:500, Peptron) polyclonal and anti-parkin (1:2,000, Santa Cruz Biotechnology) monoclonal antibodies, respectively.

E3 Ligase Activity of Purified Recombinant Parkin Proteins

Parkin E3 ligase activity was measured by using an auto-ubiquitination assay (Boston Biochem) conducted according to the manufacturers' instructions. Briefly, 1 μg of purified parkin proteins were reacted with 1 μM E1, 50 μM E2, 1 mM histidine-tagged Ubiquitin and 10 mM Mg-ATP for 1 hr at 37°C, followed by western blot with anti-Ubiquitin antibody (1:1,000, Enzo Life Science). His-NM23 (HN) was used as a negative control protein.

Apoptosis Assays

Terminal dUTP nick-end labeling (TUNEL) assays were conducted according to the manufacturers’ instructions (Roche). Mouse dopaminergic neuronal (CATH.a) cells (Korea Cell Line Bank) were plated (3×10^3 for low and 5×10^3 for high confluence) and their equivalent cell density at 5% (Low) and 70% (High) confluence was confirmed by cell counting prior to the experiment. Human brain tumor (SH-SY5Y) cells (Korea Cell Line Bank) were also cultured and confirmed the equivalent cell density (50%). These cells were pre-treated with 50 μM and 100 μM 6-hydroxydopamine (6-OHDA) for 1 hr and 6 hrs respectively, followed by treatment with 2.5 μM recombinant parkin proteins for 2.5 hrs at 37°C and analyzed for changes in cell survival.

MPTP-Induced Parkinson’s Disease Mouse Model

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (Sigma-Aldrich, St. Louis, MO) was dissolved in 0.9% NaCl. For lesioning, 6-week-old C57BL/6 female mice received 3 intraperitoneal injections of MPTP (i.p., 15 mg/kg×3 times/day, 2 hrs interval) on two consecutive days. Controls were treated with 0.9% NaCl for the same time period. We confirm that animal experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee.

Measurement of Dopamine Levels in Cultured Cells, Urine And Brain Extracts

Dopamine synthesized by cultured mouse dopaminergic neuronal cells (CATH.a), present in the urine or brain or tissue extract was measured by using a commercial ELISA kit according to instructions provided by the manufacturer (GenWay, San Diego, CA). In brief, rabbit anti-dopamine antibody is added to culture supernatant, urine or tissue extract, and the immune complexes are recovered in wells coated with goat anti rabbit antibody. A second enzyme conjugated anti-dopamine antibody directed
against a different epitope produces reaction products proportion-
al to the amount of antigen as compared against a standard curve.

**Tyrosine Hydroxylase Expression**

Brains from protein (PM10) treated mice (IP, 200 µg/day×5
consecutive days) after lesioning with MPTP were isolated.
Striatum and midbrain were rapidly dissected out, the hemi-
spheres divided and the cortex removed from the surrounding
structures. The tissues were fixed with 4% paraformaldehyde for
24 hrs and cryosected (20 µm). Dopaminergic neuronal cell
marker in brain - tyrosine hydroxylase (TH) was immunostained
with anti-TH (1:1,000, Millipore, Ramona, CA) monoclonal
antibody (1:500, Santa Cruz Biotechnology, Santa Cruz, CA), and
developed with ABC kit (Vectastain kit, Vector Laboratories,
Burlingame, CA).

**Assessment of Motor Activity**

Gross motor functions of MPTP-lesioned mice were assessed by
a swim test. Mice were placed in a 37°C water bath and
video recorded. Unlesioned mice swim using all 4 legs 98% of the
time. The percent of time of each group (MPTP only, MPTP+HP
or MPTP+HPM13) spent swimming (4 legged) was measured and
expressed as a percent of the unlesioned control.

**Statistical Analysis**

All experimental data using cultured cells were expressed as
means ± S.D. for at least three independent experiments.
Statistical significance was evaluated using a two-tailed Student’s
t-test or ANOVA method. Experimental differences between
groups were assessed using paired Student’s t-tests. For animal
experiments, ANOVA for comparisons between and within
groups were used to determine the significance. Differences with
p<0.05 were considered to be statistically significant.

**Supporting Information**

**Table S1 MTD sequences with enhanced protein trans-
duction activity.** A screen of hydrophobic signal sequences
identified hydrophobic sequences (Original Sequence) from the
indicated protein sources with enhanced macromolecule trans-
duction activity. These sequences were then modified (MTD
Sequence) to produce MTD01, MTD13, MTD10, MTD151 and
MTD174. Relative CP stands for relative cell-permeability of
MTD-EGFP protein to MTS-EGFP protein determined by
RAW264.7 cell uptake. MTS is derived from FGF4. MTDs were
derived from the hydrophobic regions of predicted signal peptides
from the indicated proteins. Helix refers to the secondary structure
of the MTD sequence as appended to the cargo proteins (EGFP or
parkin), as determined by the NPSA (network protein sequence
analysis) program. Sequence numbers are from the Genbank and
NCBI entries. Original sequence indicates the hydrophobic region
of the signal sequence of the proteins. The numbers associated
with the original sequence represent the amino acid numbers of
the original protein.

**Acknowledgments**

We thank Drs. Chris Ko and Sangjun Lee for his critical comment and
many young scientists who were involved in the early stage of this study for
their technical assistance.

**Author Contributions**

Conceived and designed the experiments: DJ. Performed the experiments:
TD DJ. Analyzed the data: JK HER DJ. Wrote the paper: HER DJ.

**References**

1. Enser N, Lutz AK, Haass C, Winklhofer KF (2012) Mitochondrial dysfunction
   in Parkinson’s disease: molecular mechanisms and pathophysiological conse-
   quences. EMBO J 31: 3038–3062.
2. Martin I, Dawson VL, Dawson TM (2011) Recent advances in the genetics of
   Parkinson’s disease. Annu Rev Genomics Hum Genet 12: 301–325.
3. Walden H, Martinez-Torres RJ (2012) Regulation of Parkin E3 ubiquitin ligase
   activity. Cell Mol Life Sci 69: 3053–3067.
4. Duty S, Jenner P (2013) Animal models of Parkinson’s disease: a source of novel
treatments and clues to the cause of the disease. Br J Pharmacol 164: 1357–1391.
29. Lipski J, Nistico R, Berretta N, Guatteo E, Bernardi G, et al. (2011) L-DOPA: a
27. Sulzer D, Surmeier DJ (2013) Neuronal vulnerability, pathogenesis, and
25. Haobam R, Sindhu KM, Chandra G, Mohanakumar KP (2005) Swim-test as a
24. Tieu K (2011) A guide to neurotoxic animal models of Parkinson’s disease. Cold
22. Lim J, Duong T, Do N, Do P, Kim J, et al. (2013) Antitumor activity of cell-
21. Lim J, Kim J, Duong T, Lee G, Kim J, et al. (2012) Antitumor activity of cell-
20. Lim J, Jang G, Kang S, Lee G, Nga do TT, et al. (2011) Cell-permeable NM23
19. DiGiandomenico A, Wylezinski LS, Hawiger J (2009) Intracellular delivery of a
18. Imai Y, Soda M, Takahashi Y, Kahle PJ, et al. (2005) Parkin: a component of an
SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37: 735–749.
17. Staropoli JF, McDermott C, Martinis C, Schulman B, Demireva E, et al. (2003)
Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37: 735–749.
16. Imai Y, Soda M, Takahashi R (2000) Parkin suppresses unfolded protein stress-
15. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, et al. (2001) An unfolded
putative transmembrane polypeptide, which can lead to endoplasmic reticulum
stress, is a substrate of Parkin. Cell 105: 91–92.
14. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B (2003) Parkin suppresses
dopaminergic neuron-selective neurotoxicity induced by PaeR in Drosophila.
Neuron 37: 911–924.
13. Liu D, Liu XY, Robinson D, Burnett C, Jackson C, et al. (2004) Suppression of
Staphylococcal Enterotoxin B-Induced Toxicity by a Nuclear Import Inhibitor.
J Biol Chem 279: 19229–19246.
12. Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, et al. (2004) Lentiviral
vectors deliver a transgene to neurons in the substantia nigra in an animal model of
Parkinson’s disease. Proc Natl Acad Sci U S A 101: 17510–17513.
11. Liu D, Liu XY, Robinson D, Burnett C, Jackson C, et al. (2004) Suppression of
Staphylococcal Enterotoxin B-Induced Toxicity by a Nuclear Import Inhibitor.
J Biol Chem 279: 19229–19246.
10. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B (2003) Parkin suppresses
dopaminergic neuron-selective neurotoxicity induced by PaeR in Drosophila.
Neuron 37: 1007–1019.
9. Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, et al. (2004) Lentiviral
vectors deliver a transgene to neurons in the substantia nigra in an animal model of
Parkinson’s disease. Proc Natl Acad Sci U S A 101: 17510–17513.
8. Imai Y, Soda M, Takahashi R (2000) Parkin suppresses unfolded protein stress-
7. Staropoli JF, McDermott C, Martinis C, Schulman B, Demireva E, et al. (2003)
Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37: 735–749.
6. Rosen KM, Verrestrawaya V, Moosa CE, Fu Q, Goldberg MS, et al. (2006)
Parkin protects against mitochondrial toxins and beta-amyloid accumulation in
skeletal muscle cells. J Biol Chem 281: 12009–12106.
5. Jiang H, Ren Y, Zhao J, Feng J (2004) Parkin protects human dopaminergic
neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 13: 1745–1754.
4. Ramamoorthy A, Kandasamy SK, Lee DK, Kiatibam S, Larson RG (2007)
Structure, topology, and tilt of cell-signaling peptides containing nuclear localization
sequences in membrane bilayers determined by solid-state NMR and molecular dynamics simulation studies. Biochemistry 46: 965–975.
3. Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, et al. (2004) Lentiviral
vectors deliver a transgene to neurons in the substantia nigra in an animal model of
Parkinson’s disease. Proc Natl Acad Sci U S A 101: 17510–17513.
2. Lim J, Duong T, Lee G, Seong BL, El-Rifai W, et al. (2013) The effect of
Protein Therapy with Cell-Permeable Parkin
21. Lim J, Duong T, Lee G, Seong BL, El-Rifai W, et al. (2013) The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin. Biosurfactants 34: 6261–6271.
20. Lim J, Duong T, Lee G, Seong BL, El-Rifai W, et al. (2013) The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin. Biosurfactants 34: 6261–6271.
19. DiGiandomenico A, Wylezinski LS, Hawiger J (2009) Intracellular delivery of a
20. Lim J, Jang G, Kang S, Lee G, Nga do TT, et al. (2011) Cell-permeable NM23
blocks the maintenance and progression of established pulmonary metastasis.
Cancer Res 71: 7216–7225.
18. Imai Y, Major AS, Zienkiewicz J, Gabriel GL, Veatch RA, et al. (2013) Nuclear
transport modulation reduces hypercholesterolemia, atherosclerosis, and fatty liver.
J Am Heart Assoc 2: e000993.
17. Moore DJ, Zienkiewicz J, Kendall PL, Liu D, Liu X, et al. (2010) In vivo iot
protection by a nuclear import inhibitor in a mouse model of type 1 diabetes.
PLoS One 5: e12323.
16. Veatch RA, Liu D, Yao S, Chen Y, Liu XY, et al. (2004) Receptor/transporter-
independent targeting of functional peptides across the plasma membrane. J Biol
Chem 279: 11425–11432.
15. Jo D, Liu D, Yeo S, Collins RD, Hawiger J (2005) Intracellular protein therapy
with SOCS3 inhibits inflammation and apoptosis. Nat Med 11: 892–898.
14. DiGiandomenico A, Wylezinski LS, Hawiger J (2009) Intracellular delivery of a
cell-penetrating SOCS1 that targets IFN-γamma-signaling cascade. Sci Signal 2: ra37.
13. Lim J, Kang G, Kang S, Lee G, Nga do TT, et al. (2011) Cell-permeable NM23
blocks the maintenance and progression of established pulmonary metastasis.
Cancer Res 71: 7216–7225.
12. Lim J, Kim J, Duong T, Lee G, Kim J, et al. (2012) Antimtor activity of cell-
permeable p8(INK4c) with enhanced membrane and tissue penetration. Mol
Ther 20: 1450–1459.
11. Lim J, Duong T, Do N, Do P, Kim J, et al. (2013) Antimtor activity of cell-
permeable RUNX3 protein in gastric cancer cells. Clin Cancer Res 19: 680–
690.
10. Masarano JM, Gong L, Kalaga H, Baker I, Wyatt RJ (1996) Dopamine induces
apoptotic cell death of a catecholaminergic cell line derived from the central
nervous system. Mol Pharmacol 50: 1309–1315.
9. Tieu K (2011) A guide to neurotoxic animal models of Parkinson’s disease. Cold
Spring Harb Perspect Med 2: 120080.
8. Imai Y, Soda M, Takahashi Y, Kahle PJ, et al. (2005) Parkin: a component of an
SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37: 735–749.
7. Staropoli JF, McDermott C, Martinis C, Schulman B, Demireva E, et al. (2003)
Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37: 735–749.
6. Rosen KM, Verrestrawaya V, Moosa CE, Fu Q, Goldberg MS, et al. (2006)
Parkin protects against mitochondrial toxins and beta-amyloid accumulation in
skeletal muscle cells. J Biol Chem 281: 12009–12106.
5. Jiang H, Ren Y, Zhao J, Feng J (2004) Parkin protects human dopaminergic
neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 13: 1745–1754.
4. Ramamoorthy A, Kandasamy SK, Lee DK, Kiatibam S, Larson RG (2007)
Structure, topology, and tilt of cell-signaling peptides containing nuclear localization
sequences in membrane bilayers determined by solid-state NMR and molecular dynamics simulation studies. Biochemistry 46: 965–975.
3. Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, et al. (2004) Lentiviral
vectors deliver a transgene to neurons in the substantia nigra in an animal model of
Parkinson’s disease. Proc Natl Acad Sci U S A 101: 17510–17513.
2. Lim J, Duong T, Lee G, Seong BL, El-Rifai W, et al. (2013) The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin. Biosurfactants 34: 6261–6271.
1. Ramamoorthy A, Kandasamy SK, Lee DK, Kiatibam S, Larson RG (2007)
Structure, topology, and tilt of cell-signaling peptides containing nuclear localization
sequences in membrane bilayers determined by solid-state NMR and molecular dynamics simulation studies. Biochemistry 46: 965–975.